114 related articles for article (PubMed ID: 6779102)
1. DOPA metabolism in neuroblastoma.
Helson L; Johnson GA; Smith R
Med Pediatr Oncol; 1980; 8(4):317-22. PubMed ID: 6779102
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma.
Eldrup E; Clausen N; Scherling B; Schmiegelow K
Scand J Clin Lab Invest; 2001; 61(6):479-90. PubMed ID: 11681538
[TBL] [Abstract][Full Text] [Related]
3. Plasma dopa and catecholamines in the diagnosis and follow-up of children with neuroblastoma.
Alvarado CS; Faraj BA; Kim TH; Camp VM; Bain RP; Ragab AH
Am J Pediatr Hematol Oncol; 1985; 7(3):221-7. PubMed ID: 3934994
[TBL] [Abstract][Full Text] [Related]
4. Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma.
Boomsma F; Ausema L; Hakvoort-Cammel FG; Oosterom R; Man in't Veld AJ; Krenning EP; Hahlen K; Schalekamp MA
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1045-52. PubMed ID: 2503383
[TBL] [Abstract][Full Text] [Related]
5. 3,4-dihydroxyphenylalanine (DOPA) metabolism in screening-detected and non-screening-detected neuroblastoma.
Ikeda H; Suzuki N; Takahashi A; Kuroiwa M; Matsuyama S
Pediatr Hematol Oncol; 1996; 13(1):21-32. PubMed ID: 8718500
[TBL] [Abstract][Full Text] [Related]
6. Catecholamine metabolism in neuroblastoma.
LaBrosse EH; Comoy E; Bohuon C; Zucker JM; Schweisguth O
J Natl Cancer Inst; 1976 Sep; 57(3):633-8. PubMed ID: 10450
[TBL] [Abstract][Full Text] [Related]
7. 3,4-dihydroxyphenylalanine (DOPA) decarboxylase deficiency and resultant high levels of plasma DOPA and dopamine in unfavorable neuroblastoma.
Ikeda H; Matsuyama S; Suzuki N; Takahashi A; Kuroiwa M
Hypertens Res; 1995 Jun; 18 Suppl 1():S209-10. PubMed ID: 8529065
[TBL] [Abstract][Full Text] [Related]
8. Determination of urinary vanillactic acid and plasma dihydroxyphenylalanine as markers of non-secreting neuroblastoma by high-performance liquid chromatography with electrochemical detection.
Jouve J; Bakri D; Herault J; Muh JP
J Chromatogr; 1991 Jul; 567(2):331-41. PubMed ID: 1939466
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of catecholamine biosynthesis by carbidopa and metyrosine in neuroblastoma.
Anton AH; Crumrine RS; Stern RC; Izant RJ
Pediatr Pharmacol (New York); 1983; 3(2):107-17. PubMed ID: 6425794
[TBL] [Abstract][Full Text] [Related]
10. Determination of 3,4-dihydroxyphenylalanine (DOPA) in plasma and cerebrospinal fluid by high performance liquid chromatography with electrochemical detection.
Boomsma F; van der Hoorn FA; Man in 't Veld AJ; Schalekamp MA
Clin Chim Acta; 1988 Nov; 178(1):59-69. PubMed ID: 3147824
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of L-3,4-dihydroxyphenylalanine-2,5,6-3H and 3,4-dihydroxyphenylethylamine-2-14C in a patient with neuroblastoma.
Imashuku S; LaBrosse EH
J Clin Endocrinol Metab; 1971 Feb; 32(2):241-53. PubMed ID: 5539035
[No Abstract] [Full Text] [Related]
12. Elevation of cerebrospinal fluid catecholamine metabolites in patients with intracranial tumors of neuroectodermal origin.
Bostrom B; Mirkin BL
J Clin Oncol; 1987 Jul; 5(7):1090-7. PubMed ID: 3598613
[TBL] [Abstract][Full Text] [Related]
13. 3,4-dihydroxyphenylalanine (dopa) metabolism and retinoic acid induced differentiation in human neuroblastoma.
Ikeda H; Pastuszko A; Ikegaki N; Kennett RH; Wilson DF
Neurochem Res; 1994 Dec; 19(12):1487-94. PubMed ID: 7877718
[TBL] [Abstract][Full Text] [Related]
14. Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma.
Goldstein DS; Stull R; Eisenhofer G; Sisson JC; Weder A; Averbuch SD; Keiser HR
Ann Intern Med; 1986 Dec; 105(6):887-8. PubMed ID: 3096183
[No Abstract] [Full Text] [Related]
15. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
Tuchman M; Ramnaraine ML; Woods WG; Krivit W
Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
[TBL] [Abstract][Full Text] [Related]
16. Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.
Pletscher A; Bartholini G; Tissot R
Brain Res; 1967 Feb; 4(1):106-9. PubMed ID: 6029941
[No Abstract] [Full Text] [Related]
17. Radioenzymatic assay of DOPA (3,4-dihydroxyphenylalanine).
Johnson GA; Gren JM; Kupiecki R
Clin Chem; 1978 Nov; 24(11):1927-30. PubMed ID: 709823
[TBL] [Abstract][Full Text] [Related]
18. Studies on tyrosine hydroxylase in neuroblastoma in relation to urinary levels of catecholamine metabolites.
Imashuku S; Takada H; Sawada T; Nakamura T; LaBrosse EH
Cancer; 1975 Aug; 36(2):450-7. PubMed ID: 239788
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels.
Granchi D; Corrias MV; Garaventa A; Baglìo SR; Cangemi G; Carlini B; Paolucci P; Giunti A; Baldini N
Bone; 2011 Jan; 48(1):152-9. PubMed ID: 20603237
[TBL] [Abstract][Full Text] [Related]
20. Elevation of lumbar cerebrospinal fluid catecholamine metabolites in patients with cranial and/or intracranial metastatic neuroblastoma.
Bostrom B; Mirkin BL
Prog Clin Biol Res; 1988; 271():557-64. PubMed ID: 3406019
[No Abstract] [Full Text] [Related]
[Next] [New Search]
